3 results
Approved WMOCompleted
Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…
Approved WMORecruiting
The objective is to determine whether etidronate can halt or attenuate disease progression in patients with Fahr*s disease or syndrome.
Approved WMOCompleted
The primary objective is to show that the ORION SYSTEM is safe and performs as intended.